Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

摘要: Objective To compare the efficacy of adalimumab versus placebo in reducing spinal and sacroiliac (SI) joint inflammation, by magnetic resonance imaging (MRI) patients with active ankylosing spondylitis (AS). Methods This was a randomized, multicenter, double-blind, placebo-controlled study. Patients (n = 82) received 40 mg or every other week during an initial 24-week double-blind period. MRIs both spine SI joints were obtained at baseline, 12, 52. Spinal inflammation measured using Spondyloarthritis Research Consortium Canada (SPARCC) MRI index. Results The SPARCC score placebo-treated increased mean 9.4% from compared decrease 53.6% adalimumab-treated (P < 0.001); decreased 12.7% baseline 52.9% 0.017). The response maintained Placebo-treated switched to open-label treatment 24 experienced similar reductions Similar large scores noted, even who failed meet ASsessment Ankylosing Spondylitis (International Working Group) criteria (nonresponders) 12 weeks. In patients, reduced C-reactive protein concentration significantly associated improvement 0.018). Conclusion Adalimumab AS after weeks treatment, these improvements for up 52